14 results on '"Planchamp, François"'
Search Results
2. Texte court rédigé à partir de la recommandation nationale de bonnes pratiques cliniques « Conduites à tenir initiales devant des patientes atteintes d’un cancer épithélial de l’ovaire » élaborée par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY et labélisée par l’INCa »
- Author
-
Lavoue, Vincent, Huchon, Cyrille, Akladios, Cherif, Alfonsi, Pascal, Bakrin, Naoual, Ballester, Marcos, Bendifallah, Sofiane, Bolze, Pierre-Adrien, Bonnet, Fabrice, Bourgin, Charlotte, Chabbert-Buffet, Nathalie, Collinet, Pierre, Courbiere, Blandine, De la Motte Rouge, Thibault, Devouassoux-Shisheboran, Mojgan, Falandry, Claire, Ferron, Gwenal, Fournier, Laure, Gladieff, Laurence, Golfier, François, Gouy, Sébastien, Guyon, Frédérique, Lambaudie, Eric, Leary, Alexandra, Lecuru, Fabrice, Lefrere-Belda, Marie-Aude, Leblanc, Eric, Lemoine, Adrien, Narducci, Fabrice, Ouldamer, Lobna, Pautier, Patricia, Planchamp, François, Pouget, Nicolas, Ray-Coquard, Isabelle, Rousset-Jablonski, Christine, Senechal-Davin, Claire, Touboul, Cyril, Thomassin-Naggara, Isabelle, Uzan, Catherine, You, Benoit, and Daraï, Emile
- Published
- 2019
- Full Text
- View/download PDF
3. Bulletin de synthèse de veille 2006: Standards, Options et Recommandations. Prise en charge des patients atteints de carcinome de site primitif inconnu
- Author
-
Bugat, Roland, Planchamp, François, Lesimple, Thierry, Voigt, Jean-Jacques, Culine, Stéphane, Lortholary, Alain, Merrouche, Yacine, Ganem, Gérard, Kaminsky, Marie-Christine, Négrier, Sylvie, Pérol, Maurice, Fizazi, Karim, and Blot, Emmanuel
- Published
- 2007
- Full Text
- View/download PDF
4. Synthèse de veille 2006 Recommandations pour la pratique clinique : utilisation de la TEP-FDG dans les cancers du rein, de la prostate, du testicule et de la vessie
- Author
-
Bourguet, Patrick, Planchamp, François, Montravers, Françoise, and Vincendeau, Sébastien
- Published
- 2007
- Full Text
- View/download PDF
5. [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]
- Author
-
Rousset-Jablonski, Christine, Selle, Frédéric, Adda-Herzog, Elodie, Planchamp, François, Selleret, Lise, Pomel, Christophe, Chabbert-Buffet, Nathalie, Darai, Emile, Pautier, Patricia, Trémollières, Florence, Guyon, Frédéric, Rouzier, Roman, Laurence, Valérie, Chopin, Nicolas, Faure-Conter, Cécile, Bentivegna, Enrica, Vacher-Lavenu, Marie-Cécile, Lhomme, Catherine, Floquet, Anne, Treilleux, Isabelle, Lecuru, Fabrice, Gouy, Sébastien, Kalbacher, Elsa, Genestie, Catherine, de La Motte Rouge, Thibault, Ferron, Gwenaël, Devouassoux-Shisheboran, Mojgan, Kurtz, Jean-Emmanuel, Namer, Moïse, Joly, Florence, Pujade-Lauraine, Eric, Grynberg, Michael, Querleu, Denis, Morice, Philippe, Gompel, Anne, Ray-Coquard, Isabelle, Centre Léon Bérard [Lyon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Molécules Thérapeutiques in silico (MTI), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), École Nationale de la Statistique et de l'Administration Économique (ENSAE Paris), Institut Gustave Roussy (IGR), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Beninois pour l'Environnement et le développement économique et Social (CEBEDES), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Pitié-Salpêtrière [AP-HP], Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Claudius Regaud, Service d'Anatomo-Pathologie [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Les Hôpitaux Universitaires de Strasbourg (HUS), Cancérologie (Inserm U599/IPC), Université de la Méditerranée - Aix-Marseille 2-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Oncologie médicale [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service d'Oncologie Médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Hôpital Hôtel-Dieu [Paris], Unité de Biologie Fonctionnelle et Adaptative (BFA (UMR_8251 / U1133)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de chirurgie générale [Gustave Roussy], Unité de Gynécologie, Health Service and Performance Research (HESPER), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Alliance Pour la Recherche En Cancérologie [CHU Tenon] (APREC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Gynécologie-obstétrique et médecine de la reproduction - Maternité [CHU Tenon], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'anatomie pathologique [CHU Pitié-Salpêtrière], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-CRLCC Eugène Marquis (CRLCC)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Tumeurs germinales ,Fertilité ,Delphi Technique ,Borderline ovarian tumor ,Menopause, Premature ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Carcinoma, Ovarian Epithelial ,Rare Diseases ,Sex cord tumor ,Germ cell tumor ,Humans ,Neoplasms, Glandular and Epithelial ,Rare ovarian tumor ,Hormone therapy ,Ovarian Neoplasms ,Contraindications, Drug ,Fertility Preservation ,Tumeur borderline ,Neoplasms, Germ Cell and Embryonal ,Traitement hormonal ,Contraception ,Fertility ,Female ,Tumeurs des cordons sexuels ,Tumeur rare de l’ovaire ,Infertility, Female - Abstract
National audience; Introduction - Rare ovarian tumors include complex borderline ovarian tumors, sex-cord tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility preservation, infertility management and contraindications for hormonal contraception or menopause hormone therapy are frequent issues in clinical practice. A panel of experts from the French national network dedicated to rare gynaecological cancers, and of experts in reproductive medicine and gynaecology have worked on guidelines about fertility preservation, contraception and menopause hormone therapy in women treated for ovarian rare tumors. Methods - A panel of 39 experts from different specialties contributed to the preparation of the guidelines, following the DELPHI method (formal consensus method). Statements were drafted after a systematic literature review, and then rated through two successive rounds. Results - Thirty-five recommendations were selected, and concerned indications for fertility preservation, contraindications for ovarian stimulation (in the context of fertility preservation or for infertility management), contraceptive options (especially hormonal ones), and menopause hormone therapy for each tumor type. Overall, prudence has been recommended in the case of potentially hormone-sensitive tumors such as sex cord tumors, serous and endometrioid low-grade adenocarcinomas, as well as for high-risk serous borderline ovarian tumors. Discussion - In the context of a scarce literature, a formal consensus method allowed the elaboration of guidelines, which will help clinicians in the management of these patients.
- Published
- 2018
6. [Management of the nodal disease in vulvar cancers. The ESGO guidelines].
- Author
-
Querleu D, Rychlik A, Guyon F, Floquet A, and Planchamp F
- Subjects
- Female, Humans, Practice Guidelines as Topic, Lymphatic Metastasis therapy, Vulvar Neoplasms pathology, Vulvar Neoplasms therapy
- Abstract
The European Society of Gynaecologic Oncology (ESGO) guidelines cover the whole field of common clinical situations in gynecologic oncology. Their elaboration follows a strict process including a systematic review of the literature, the setting up of a group of expert on the basis of scientific production, geographical balance, and multidisciplinarity, and an external review by users and patients. The recommendations for the management of vulvar cancer were elaborated in 2015 and published in 2017. They are available in open access on the ESGO website, and can be incorporated in clinical practice using the free ESGO guidelines smartphone application. This review is a selection of the sections addressing the diagnostic and strategical aspects of the management of lymph nodal disease in vulvar cancer. An additional review of the recent literature published since 2015 has been carried out. The management of nodal disease in vulvar cancer encompasses a diagnostic and a therapeutic component. Clinical and imaging assessment still play a major role, whilst the identification of the sentinel node is currently a mainstay of assessment of the nodal status in early vulvar cancer. The therapeutic component is based on the rational use of full lymph node dissection and (chemo)radiation., (Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
7. [Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].
- Author
-
Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, and Daraï E
- Subjects
- Antineoplastic Agents therapeutic use, Bevacizumab therapeutic use, Chemotherapy, Adjuvant, Female, France, Humans, Hyperthermia, Induced, Lymph Node Excision, Magnetic Resonance Imaging, Phthalazines therapeutic use, Piperazines therapeutic use, Societies, Medical, Ultrasonography, Carcinoma, Ovarian Epithelial diagnostic imaging, Carcinoma, Ovarian Epithelial drug therapy, Carcinoma, Ovarian Epithelial pathology, Carcinoma, Ovarian Epithelial surgery, Fallopian Tube Neoplasms diagnostic imaging, Fallopian Tube Neoplasms drug therapy, Fallopian Tube Neoplasms pathology, Fallopian Tube Neoplasms surgery, Ovarian Neoplasms diagnostic imaging, Ovarian Neoplasms drug therapy, Ovarian Neoplasms pathology, Ovarian Neoplasms surgery, Peritoneal Neoplasms diagnostic imaging, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms pathology, Peritoneal Neoplasms surgery
- Abstract
Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). In case of ovarian, Fallopian tube or primitive peritoneal cancer of FIGO III-IV stages, thoraco-abdomino-pelvic CT scan with injection (grade B) is recommended. Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A)., (Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
8. [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].
- Author
-
Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Chabbert-Buffet N, Daraï E, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, de la Motte Rouge T, Ferron G, Devouassoux-Shisheboran M, Kurtz JE, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, and Ray-Coquard I
- Subjects
- Carcinoma, Ovarian Epithelial, Contraindications, Drug, Delphi Technique, Female, Humans, Neoplasms, Germ Cell and Embryonal pathology, Neoplasms, Germ Cell and Embryonal therapy, Neoplasms, Glandular and Epithelial pathology, Neoplasms, Glandular and Epithelial therapy, Ovarian Neoplasms pathology, Rare Diseases pathology, Contraception methods, Fertility Preservation methods, Infertility, Female therapy, Menopause, Premature, Ovarian Neoplasms therapy, Rare Diseases therapy
- Abstract
Introduction: Rare ovarian tumors include complex borderline ovarian tumors, sex-cord tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility preservation, infertility management and contraindications for hormonal contraception or menopause hormone therapy are frequent issues in clinical practice. A panel of experts from the French national network dedicated to rare gynaecological cancers, and of experts in reproductive medicine and gynaecology have worked on guidelines about fertility preservation, contraception and menopause hormone therapy in women treated for ovarian rare tumors., Methods: A panel of 39 experts from different specialties contributed to the preparation of the guidelines, following the DELPHI method (formal consensus method). Statements were drafted after a systematic literature review, and then rated through two successive rounds., Results: Thirty-five recommendations were selected, and concerned indications for fertility preservation, contraindications for ovarian stimulation (in the context of fertility preservation or for infertility management), contraceptive options (especially hormonal ones), and menopause hormone therapy for each tumor type. Overall, prudence has been recommended in the case of potentially hormone-sensitive tumors such as sex cord tumors, serous and endometrioid low-grade adenocarcinomas, as well as for high-risk serous borderline ovarian tumors., Discussion: In the context of a scarce literature, a formal consensus method allowed the elaboration of guidelines, which will help clinicians in the management of these patients., (Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
9. [Surgical management of ovarian cancer: Trends in clinical practice].
- Author
-
Querleu D, Meurette J, Daraï E, Morice P, and Planchamp F
- Subjects
- Databases, Factual, Female, France, Hospitals, High-Volume statistics & numerical data, Hospitals, High-Volume trends, Hospitals, Low-Volume statistics & numerical data, Hospitals, Low-Volume trends, Humans, Ovarian Neoplasms pathology, Clinical Coding, Ovarian Neoplasms surgery
- Abstract
Surgery has evolved as a mainstay of the management of ovarian cancer since evidence of the major benefit of complete surgery, i.e. achieving complete resection of the disease without visible macroscopic residue in a comprehensively explored abdominal cavity, has been made available. This objective may be difficult to complete in case of advanced ovarian cancer, as it requires the use of advanced techniques of peritoneal and visceral surgery, in the setting of adapted perioperative care, generally in institutions where the caseload is sufficient to ensure an appropriate surgical experience, and where specifically trained surgeons are available. In this paper using the data from the French national database PMSI, evidence of an evolution of the proportion of patients managed in centers where more than 20 patients a year are operated is shown. However, the recommendations of the governmental Plans Cancers are far from universally implemented., (Copyright © 2016 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
10. [Loco-regional treatments of the metastatic sites for patients with pauci-metastatic cutaneous melanoma (without brain metastasis): French national guidelines].
- Author
-
Sassolas B, Mourrégot A, Thariat J, Tiffet O, Dygai-Cochet I, Mirabel X, Truc G, Cupissol D, Modiano P, Combemale P, Bedane C, Derrey S, Lamant L, Lubrano V, Siegrist S, Rougé-Bugat MÈ, Mazeau-Woynar V, Verdoni L, Planchamp F, and Leccia MT
- Subjects
- Humans, Liver Neoplasms secondary, Skin Neoplasms therapy, Melanoma, Cutaneous Malignant, Bone Neoplasms secondary, Bone Neoplasms therapy, Digestive System Neoplasms, Liver Neoplasms therapy, Lung Neoplasms secondary, Lung Neoplasms therapy, Melanoma secondary, Melanoma therapy, Skin Neoplasms pathology
- Abstract
Introduction: The last years are marked by the emergence of new molecules for the treatment of metastatic cutaneous melanoma with a significant benefit on the survival. Besides, some techniques are in development for the loco-regional treatment of the metastatic sites, bringing new therapeutic perspectives. However, their respective use and place in the therapeutic strategy are debated by healthcare professionals., Objective: The French National Cancer Institute leads a national clinical practice guidelines project since 2008. It realized a review of these modalities of treatment and developed recommendations., Methods: The clinical practice guidelines development process is based on systematic literature review and critical appraisal by a multidisciplinary expert workgroup. The recommendations are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines are reviewed by independent practitioners in cancer care delivery., Results: This article presents recommendations for loco-regional treatments of the pulmonary, bone, cutaneous, hepatic and digestive metastatic sites for patients with pauci-metastatic cutaneous melanoma.
- Published
- 2014
- Full Text
- View/download PDF
11. [Clinical practice guidelines 2008 for the surgical treatment, medical first-line and consolidation treatments of patients with epithelial ovarian cancer--update. According to the methodology of Standards, Options: Recommendations (SOR)].
- Author
-
Lhommé C, Morice P, Planchamp F, Daraï E, Joly F, Leblanc E, Lefranc JP, and Querleu D
- Subjects
- Chemotherapy, Adjuvant, Female, France, Humans, Neoplasm Staging, Neoplasms, Glandular and Epithelial pathology, Neoplasms, Glandular and Epithelial surgery, Ovarian Neoplasms pathology, Ovarian Neoplasms surgery, Radiotherapy, Adjuvant, Neoplasms, Glandular and Epithelial therapy, Ovarian Neoplasms therapy
- Abstract
Context: Ovarian cancers represent the 4th cause of mortality by cancer for women in France and were responsible of more than 3,000 deaths in 2005. The Standards, Options: Recommendations (SOR) project has been undertaken by the French National Federation of Cancers Centers is now part of the French National Cancer Institute since the 1st of may 2008. The project involves the development and updating of evidence-based clinical practice guidelines (CPG) in oncology. Following the monitoring process, we identified new data conferring sufficient elements to justify an updating of the CPG concerning the surgical, the medical fi rst-line and consolidation treatments of epithelial ovarian cancers., Objectives: To update the CPG according to the methodology SOR.
- Published
- 2008
- Full Text
- View/download PDF
12. [2006 technology monitoring report: clinical practice guideline: use of FDG-PET in kidney, prostate, testis and bladder cancers].
- Author
-
Bourguet P, Planchamp F, Montravers F, and Vincendeau S
- Subjects
- France, Humans, Image Processing, Computer-Assisted, Male, Medical Laboratory Science, Fluorodeoxyglucose F18, Kidney Neoplasms diagnostic imaging, Positron-Emission Tomography, Prostatic Neoplasms diagnostic imaging, Radiopharmaceuticals, Testicular Neoplasms diagnostic imaging, Urinary Bladder Neoplasms diagnostic imaging
- Published
- 2007
- Full Text
- View/download PDF
13. [Recommendations for clinical practice: use of TEP-FDG in cancer of the esophagus, stomach, colon and rectum, anal canal, large intestine, pancreas and bile ducts, liver and endocrine tumors (digestive system)].
- Author
-
Bourguet P, Planchamp F, Monteil J, Metges JP, Mitry E, and Tubiana-Mathieu N
- Subjects
- Anus Neoplasms diagnostic imaging, Bile Duct Neoplasms diagnostic imaging, Colorectal Neoplasms diagnostic imaging, Endocrine Gland Neoplasms diagnostic imaging, Esophageal Neoplasms diagnostic imaging, Gastrointestinal Neoplasms diagnostic imaging, Humans, Intestine, Large diagnostic imaging, Liver Neoplasms diagnostic imaging, Pancreatic Neoplasms diagnostic imaging, Radiopharmaceuticals, Stomach Neoplasms diagnostic imaging, Digestive System Neoplasms diagnostic imaging, Fluorodeoxyglucose F18, Positron-Emission Tomography standards
- Published
- 2007
14. [Recommendation for clinical practice: use of PET-FDG in cancer of the kidney, prostate, testicles, and the urinary bladder].
- Author
-
Bourguet P, Planchamp F, Montravers F, Vincendeau S, Courbon F, Edeline V, Helal BO, Rossi D, and Villers A
- Subjects
- Female, France, Humans, Male, Kidney Neoplasms diagnostic imaging, Positron-Emission Tomography methods, Prostatic Neoplasms diagnostic imaging, Radiopharmaceuticals, Testicular Neoplasms diagnostic imaging, Urinary Bladder Neoplasms diagnostic imaging
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.